RT Journal Article
T1 Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
A1 Piñana, Jose Luis
A1 Rodriguez-Belenguer, Pablo
A1 Caballero, Dolores
A1 Martino, Rodrigo
A1 Lopez-Corral, Lucia
A1 Terol, Maria-Jose
A1 Vazquez, Lourdes
A1 Calabuig, Marisa
A1 Sanz-Linares, Gabriela
A1 Marin-Jimenez, Francisca
A1 Alonso, Carmen
A1 Montoro, Juan
A1 Ferrer, Elena
A1 Facal, Ana
A1 Pascual, Maria-Jesus
A1 Rodriguez-Fernandez, Alicia
A1 Olave, María T
A1 Cascales-Hernandez, Almudena
A1 Gago, Beatriz
A1 Hernandez-Rivas, Jose-Angel
A1 Villalon, Lucia
A1 Corona, Magdalena
A1 Roldan-Perez, Alicia
A1 Ribes-Amoros, Julia
A1 Gonzalez-Santillana, Clara
A1 Garcia-Sanz, Ramon
A1 Navarro, David
A1 Serrano-Lopez, Antonio J
A1 Cedillo, Angel
A1 Soria-Olivas, Emilio
A1 Sureda, Anna
A1 Solano, Carlos
K1 Allogeneic stem cell transplantation
K1 Autologous stem cell transplantation
K1 Bayesian Networks
K1 CAR-T therapy
K1 COVID-19
K1 Chronic lymphocytic leukemia
K1 Hematological malignancies
K1 Immunocompromised patients
K1 Moderna mRNA-1273
K1 Non-Hodgkin lymphoma
K1 Pfizer-BioNTech BNT162b2
K1 Probabilistic graphical models
K1 Respiratory virus
K1 SARS-CoV-2 vaccines
K1 mRNA vaccine
AB Prior studies of antibody response after full SARS-CoV-2 vaccination in hematological patients have confirmed lower antibody levels compared to the general population. Serological response in hematological patients varies widely according to the disease type and its status, and the treatment given and its timing with respect to vaccination. Through probabilistic machine learning graphical models, we estimated the conditional probabilities of having detectable anti-SARS-CoV-2 antibodies at 3-6 weeks after SARS-CoV-2 vaccination in a large cohort of patients with several hematological diseases (n= 1166). Most patients received mRNA-based vaccines (97%), mainly Moderna® mRNA-1273 (74%) followed by Pfizer-BioNTech® BNT162b2 (23%). The overall antibody detection rate at 3 to 6 weeks after full vaccination for the entire cohort was 79%. Variables such as type of disease, timing of anti-CD20 monoclonal antibody therapy, age, corticosteroids therapy, vaccine type, disease status, or prior infection with SARS-CoV-2 are among the most relevant conditions influencing SARS-CoV-2-IgG-reactive antibody detection. A lower probability of having detectable antibodies was observed in patients with B-cell non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibodies within 6 months before vaccination (29.32%), whereas the highest probability was observed in younger patients with chronic myeloproliferative neoplasms (99.53%). The Moderna® mRNA-1273 compound provided higher probabilities of antibody detection in all scenarios. This study depicts conditional probabilities of having detectable antibodies in the whole cohort and in specific scenarios such as B cell NHL, CLL, MM, and cMPN that may impact humoral responses. These results could be useful to focus on additional preventive and/or monitoring interventions in these highly immunosuppressed hematological patients.
PB Springer
YR 2022
FD 2022-07-02
LK http://hdl.handle.net/10668/19697
UL http://hdl.handle.net/10668/19697
LA en
NO Piñana JL, Rodríguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol MJ, et al. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. Ann Hematol. 2022 Sep;101(9):2053-2067
DS RISalud
RD Apr 9, 2025